NLS Pharmaceutics Stock (NLSP) Why The Price Surged Today

By Amit Chowdhry ● Jan 4, 2022
  • The stock price of NLS Pharmaceutics AG (NASDAQ: NLSP) increased by over 80% during intraday trading today. This is why it happened.

The stock price of NLS Pharmaceutics AG (NASDAQ: NLSP) – a Swiss clinical-stage pharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders – increased by over 80% during intraday trading today. This is why it happened. Investors are responding positively to NLS Pharmaceutics announcing that the United States Patent and Trademark Office (USPTO) has granted the Company U.S. Patent No. 11207271, entitled A MAZINDOL IR/SR MULTILAYER TABLET AND ITS USE FOR THE TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD).

This patent covers oral formulations containing immediate-release and sustained-release layers of mazindol and their use in treating attention deficit disorders (ADD or ADHD), a related deficit of alertness or decline of vigilance, or excessive daytime sleepiness including narcolepsy or idiopathic hypersomnia.

KEY QUOTE:

“Our intellectual property estate has been significantly strengthened since our initial public offering in February 2021, putting NLS in a solid position as we anticipate reporting Phase 2a results for Quilience (mazindol ER) to treat narcolepsy in the first quarter of 2022. We now have issued patents in major markets including the U.S., Europe, Canada, and South Korea covering our extended-release formulation of mazindol. These recently issued patents augment the Orphan Drug Designations that have been granted for Quilience in both the U.S. and Europe. Most patients with narcolepsy remain unsatisfied with current treatment options, and we believe that Quilience has potential to fill a major need in the market given mazindol’s history of safety and evidence of effectiveness in treating the symptoms of narcolepsy. We remain focused on bringing this treatment option to patients suffering from narcolepsy and potentially other sleep-wake disorders as soon as possible.”

— Alex Zwyer, Chief Executive Officer of NLS

Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.